GeoVax Labs (GOVX US): Synthetic Expert Call Transcript (20 Sep 2026)
MVA Platform Commercial Feasibility: While Modified Vaccinia Ankara (MVA) viral vectors offer superior thermal stability and robust T-cell...
87 Views
IPO Databook: GeoVax Labs (GOVX US) - Sep 2026
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid...
86 Views
Biopharma Week in Review - August 19, 2024
PFE/BNTX COVID-flu vaccine missed on one endpoint, extending MRNA’s lead and allowing SNY/NVAX to catch up. SYRS ended up futile on AML.
339 Views
No more insights